Vestal Point Capital, LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Vestal Point Capital, LP reported 68 stock positions worth $4.3 billion. Its top holding was Biomarin Pharmaceutical (BMRN) at 8.1% of the portfolio, followed by Neurocrine Biosciences (NBIX, 7.4%) and Abivax SA-ADR (ABVX, 7.3%). Compared with Q1 2026, it opened 9 new positions, sold out of 31, added to 31 and reduced 22. The biggest buy was United Therapeutics (UTHR, shares +480%) and the biggest sale Revolution Medicines (RVMD, shares −81%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001974915
- Portfolio Value
- $4.3B (Q2 2026)
- SEC Filing
- 0001974915-26-000005 ↗ filed Aug 14, 2026
Holdings Value
Holdings 68 stocks · $4.3B
| BMRN Biomarin Pharmaceutical Inc. | 8.06% | 6,025,000 | $344.8M | Add +68.5% |
| NBIX Neurocrine Biosciences Inc. | 7.40% | 1,880,000 | $316.8M | Add +50.4% |
| ABVX Abivax SA-ADR | 7.32% | 2,349,443 | $313.1M | Add +56.6% |
| UTHR United Therapeutics Corp. | 5.51% | 435,000 | $235.7M | Add +480.0% |
| ELVN Enliven Therapeutics Inc. | 4.74% | 4,000,000 | $203.0M | Add +23.1% |
| NRIX Nurix Therapeutics Inc. | 4.56% | 8,050,000 | $195.3M | Add +23.9% |
| BCAX Bicara Therapeutics Inc. | 3.64% | 5,250,000 | $155.9M | Reduce -3.2% |
| TSHA Taysha Gene Therapies Inc. | 3.09% | 19,415,000 | $132.2M | Add +7.9% |
| ARWR Arrowhead Pharmaceuticals Inc. | 3.00% | 1,575,000 | $128.4M | Reduce -30.8% |
| ABT Abbott Laboratories | 2.97% | 1,400,000 | $127.0M | New |
| ZBH Zimmer Biomet Holdings Inc. | 2.82% | 1,400,000 | $120.5M | Add +636.8% |
| IRON Disc Medicine Inc. | 2.65% | 1,550,000 | $113.4M | Add +121.4% |
| GLUE Monte Rosa Therapeutics Inc. | 2.60% | 4,600,000 | $111.3M | Add +27.6% |
| PODD Insulet Corp. | 2.38% | 670,000 | $102.0M | Add +1224.1% |
| ASND Ascendis Pharma A/S | 2.34% | 375,000 | $100.0M | No change |
| AZN Astrazeneca PLC | 1.99% | 450,000 | $85.3M | Add +350.0% |
| SNY Sanofi-ADR | 1.99% | 2,000,000 | $85.3M | Add +42.9% |
| RVMD Revolution Medicines Inc. | 1.97% | 450,000 | $84.3M | Reduce -81.0% |
| BCRX Biocryst Pharmaceuticals Inc. | 1.94% | 8,300,000 | $83.0M | Add +18.1% |
| DYN Dyne Therapeutics Inc. | 1.75% | 3,375,000 | $75.0M | Reduce -15.6% |
| NKTR Nektar Therapeutics | 1.63% | 1,000,000 | $69.8M | Add +250.9% |
| GMED Globus Medical Inc. Class A | 1.57% | 850,000 | $67.2M | Add +39.2% |
| TARS Tarsus Pharmaceuticals Inc. | 1.54% | 1,050,000 | $66.1M | Add +425.0% |
| IMTX Immatics NV | 1.46% | 6,175,000 | $62.6M | No change |
| TRVI Trevi Therapeutics Inc. | 1.35% | 3,100,000 | $57.8M | Add +43.1% |
| IMCR Immunocore Holdings PLC-ADR | 1.34% | 1,800,000 | $57.1M | Reduce -34.9% |
| RGEN Repligen Corp. | 1.28% | 400,000 | $54.6M | Reduce -56.8% |
| BMY Bristol-Myers Squibb Co. | 1.08% | 800,000 | $46.1M | Reduce -20.0% |
| QURE Uniqure NV | 1.01% | 935,000 | $43.1M | Add +160.4% |
| XENE Xenon Pharmaceuticals Inc. | 0.99% | 700,000 | $42.3M | Add +9.4% |
| DRUG Bright Minds Biosciences Inc. | 0.89% | 545,000 | $38.3M | Add +10.7% |
| MDGL Madrigal Pharmaceuticals Inc. | 0.82% | 65,000 | $34.9M | Add +106.6% |
| ALC Alcon Inc. filed as ALCON AG | 0.78% | 500,000 | $33.5M | Reduce -37.5% |
| MYGN Myriad Genetics Inc. | 0.77% | 5,735,000 | $32.7M | Add +248.0% |
| RAPP Rapport Therapeutics Inc. | 0.71% | 730,000 | $30.4M | Reduce -49.2% |
| CBIO Crescent Biopharma Inc. | 0.69% | 1,630,000 | $29.3M | Add +8.7% |
| GEHC GE Healthcare Technology | 0.67% | 450,000 | $28.8M | Add +80.0% |
| INSM Insmed Inc. | 0.62% | 250,000 | $26.7M | New |
| VKTX Viking Therapeutics Inc. | 0.62% | 680,000 | $26.5M | Reduce -25.6% |
| BBNX Beta Bionics Inc. | 0.59% | 1,600,000 | $25.1M | Reduce -27.6% |
| REGN Regeneron Pharmaceuticals | 0.58% | 40,000 | $24.9M | No change |
| SLDB Solid Biosciences Inc. | 0.50% | 2,160,000 | $21.6M | Reduce -56.8% |
| ANRO Alto Neuroscience Inc. | 0.48% | 785,000 | $20.7M | Reduce -62.0% |
| TRAX First Tracks Biotherapeutics | 0.48% | 1,013,000 | $20.4M | New |
| LXEO Lexeo Therapeutics Inc. | 0.47% | 4,320,000 | $20.1M | Reduce -3.5% |
| SVRA Savara Inc. | 0.39% | 2,720,000 | $16.8M | Add +4.6% |
| DMRA Damora Therapeutics Inc. | 0.35% | 575,000 | $15.0M | Reduce -4.2% |
| SGP Spyglass Pharma Inc. | 0.35% | 670,000 | $14.9M | Add +0.5% |
| TECX Tectonic Therapeutic Inc. | 0.34% | 425,000 | $14.6M | Add +29.6% |
| AVTX Avalo Therapeutics Inc. | 0.33% | 775,000 | $14.3M | New |
| EVMN Evommune Inc. | 0.31% | 1,000,000 | $13.3M | New |
| KLRA Kailera Therapeutics Inc. | 0.30% | 575,000 | $12.7M | New |
| AVR Anteris Technologies Global | 0.23% | 1,010,000 | $9.9M | Reduce -11.8% |
| ZBIO Zenas Biopharma Inc. | 0.22% | 365,000 | $9.3M | Add +82.5% |
| VYGR Voyager Therapeutics Inc. | 0.21% | 2,625,000 | $9.2M | Reduce -12.6% |
| OKUR Onkure Therapeutics Inc. Class A | 0.19% | 1,825,699 | $8.3M | Reduce -0.8% |
| SRZN Surrozen Inc. | 0.18% | 304,669 | $7.9M | Reduce -10.0% |
| MNPR Monopar Therapeutics Inc. | 0.16% | 75,727 | $7.0M | Add +15.8% |
| ZURA Zura Bio Ltd. | 0.16% | 1,173,956 | $6.9M | Add +129.7% |
| OLMA Olema Pharmaceuticals Inc. | 0.12% | 418,551 | $5.2M | Reduce -2.3% |
| PALI Palisade Bio Inc. | 0.12% | 2,500,000 | $5.2M | No change |
| IBIO Ibio Inc. | 0.11% | 2,600,000 | $4.5M | New |
| SGMT Sagimet Biosciences Inc. Class A | 0.10% | 535,452 | $4.1M | New |
| ENGN Engene Therapeutics Inc. | 0.07% | 1,667,430 | $2.9M | Reduce -23.0% |
| RZLT Rezolute Inc. | 0.05% | 382,999 | $2.0M | New |
| NYXH Nyxoah SA | 0.03% | 843,461 | $1.4M | Reduce -2.9% |
| TENX Tenax Therapeutics Inc. | 0.02% | 53,439 | $778K | No change |
| APRE Aprea Therapeutics Inc. | 0.01% | 350,000 | $281K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| RVMD Revolution Medicines Inc. | Reduce -81.0% | 1.97% | −4.49 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −2.59 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −1.82 |
| RGEN Repligen Corp. | Reduce -56.8% | 1.28% | −1.77 |
| VERA Vera Therapeutics Inc. | Sold out | 0.00% | −1.54 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −1.47 |
| BSX Boston Scientific Corp. | Sold out | 0.00% | −1.40 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −1.38 |
| COGT Cogent Biosciences Inc. | Sold out | 0.00% | −1.32 |
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −1.09 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −1.04 |
| IMCR Immunocore Holdings PLC-ADR | Reduce -34.9% | 1.34% | −1.00 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -30.8% | 3.00% | −0.99 |
| PTGX Protagonist Therapeutics Inc. | Sold out | 0.00% | −0.96 |
| DNLI Denali Therapeutics Inc. | Sold out | 0.00% | −0.95 |
| ALC Alcon Inc. | Reduce -37.5% | 0.78% | −0.90 |
| WAT Waters Corp. | Sold out | 0.00% | −0.83 |
| ANRO Alto Neuroscience Inc. | Reduce -62.0% | 0.48% | −0.81 |
| INSP Inspire Medical Systems Inc. | Sold out | 0.00% | −0.78 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −0.68 |
| BMY Bristol-Myers Squibb Co. | Reduce -20.0% | 1.08% | −0.62 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.55 |
| RAPP Rapport Therapeutics Inc. | Reduce -49.2% | 0.71% | −0.55 |
| WST West Pharmaceutical Services | Sold out | 0.00% | −0.53 |
| SLDB Solid Biosciences Inc. | Reduce -56.8% | 0.50% | −0.50 |
| WGS Genedx Holdings Corp. | Sold out | 0.00% | −0.45 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −0.43 |
| ENGN Engene Therapeutics Inc. | Reduce -23.0% | 0.07% | −0.34 |
| DYN Dyne Therapeutics Inc. | Reduce -15.6% | 1.75% | −0.28 |
| ARVN Arvinas Inc. | Sold out | 0.00% | −0.27 |
| LXEO Lexeo Therapeutics Inc. | Reduce -3.5% | 0.47% | −0.25 |
| MPLT Maplight Therapeutics Inc. | Sold out | 0.00% | −0.24 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −0.24 |
| VKTX Viking Therapeutics Inc. | Reduce -25.6% | 0.62% | −0.21 |
| CADL Candel Therapeutics Inc. | Sold out | 0.00% | −0.15 |
| VCYT Veracyte Inc. | Sold out | 0.00% | −0.12 |
| VYGR Voyager Therapeutics Inc. | Reduce -12.6% | 0.21% | −0.11 |
| GERN Geron Corp. | Sold out | 0.00% | −0.11 |
| SRZN Surrozen Inc. | Reduce -10.0% | 0.18% | −0.09 |
| DMRA Damora Therapeutics Inc. | Reduce -4.2% | 0.35% | −0.09 |
| NVCR Novocure Ltd. | Sold out | 0.00% | −0.08 |
| URGN Urogen Pharma Ltd. | Sold out | 0.00% | −0.07 |
| PASG Passage Bio Inc. | Sold out | 0.00% | −0.07 |
| TYRA Tyra Biosciences Inc. | Sold out | 0.00% | −0.06 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -2.3% | 0.12% | −0.06 |
| NYXH Nyxoah SA | Reduce -2.9% | 0.03% | −0.04 |
| BBNX Beta Bionics Inc. | Reduce -27.6% | 0.59% | −0.03 |
| RGNX Regenxbio Inc. | Sold out | 0.00% | −0.03 |
| MGNX Macrogenics Inc. | Sold out | 0.00% | −0.02 |
| ABSI Absci Corp. | Sold out | 0.00% | −0.02 |
Portfolio Buys Q1 2026 → Q2 2026
| UTHR United Therapeutics Corp. | Add +480.0% | 5.51% | +4.26 |
| ABT Abbott Laboratories | New | 2.97% | +2.97 |
| NBIX Neurocrine Biosciences Inc. | Add +50.4% | 7.40% | +2.80 |
| ABVX Abivax SA-ADR | Add +56.6% | 7.32% | +2.65 |
| BMRN Biomarin Pharmaceutical Inc. | Add +68.5% | 8.06% | +2.41 |
| ZBH Zimmer Biomet Holdings Inc. | Add +636.8% | 2.82% | +2.34 |
| PODD Insulet Corp. | Add +1224.1% | 2.38% | +2.09 |
| NRIX Nurix Therapeutics Inc. | Add +23.9% | 4.56% | +1.75 |
| AZN Astrazeneca PLC | Add +350.0% | 1.99% | +1.44 |
| IRON Disc Medicine Inc. | Add +121.4% | 2.65% | +1.40 |
| ELVN Enliven Therapeutics Inc. | Add +23.1% | 4.74% | +1.18 |
| TARS Tarsus Pharmaceuticals Inc. | Add +425.0% | 1.54% | +1.15 |
| NKTR Nektar Therapeutics | Add +250.9% | 1.63% | +1.06 |
| GLUE Monte Rosa Therapeutics Inc. | Add +27.6% | 2.60% | +0.94 |
| QURE Uniqure NV | Add +160.4% | 1.01% | +0.84 |
| TSHA Taysha Gene Therapies Inc. | Add +7.9% | 3.09% | +0.84 |
| TRVI Trevi Therapeutics Inc. | Add +43.1% | 1.35% | +0.63 |
| INSM Insmed Inc. | New | 0.62% | +0.62 |
| MYGN Myriad Genetics Inc. | Add +248.0% | 0.77% | +0.56 |
| TRAX First Tracks Biotherapeutics | New | 0.48% | +0.48 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +106.6% | 0.82% | +0.35 |
| AVTX Avalo Therapeutics Inc. | New | 0.33% | +0.33 |
| EVMN Evommune Inc. | New | 0.31% | +0.31 |
| KLRA Kailera Therapeutics Inc. | New | 0.30% | +0.30 |
| GEHC GE Healthcare Technology | Add +80.0% | 0.67% | +0.18 |
| SNY Sanofi-ADR | Add +42.9% | 1.99% | +0.11 |
| ZBIO Zenas Biopharma Inc. | Add +82.5% | 0.22% | +0.11 |
| IBIO Ibio Inc. | New | 0.11% | +0.11 |
| GMED Globus Medical Inc. Class A | Add +39.2% | 1.57% | +0.10 |
| SGMT Sagimet Biosciences Inc. Class A | New | 0.10% | +0.10 |
| ZURA Zura Bio Ltd. | Add +129.7% | 0.16% | +0.08 |
| BCRX Biocryst Pharmaceuticals Inc. | Add +18.1% | 1.94% | +0.07 |
| MNPR Monopar Therapeutics Inc. | Add +15.8% | 0.16% | +0.06 |
| TECX Tectonic Therapeutic Inc. | Add +29.6% | 0.34% | +0.06 |
| RZLT Rezolute Inc. | New | 0.05% | +0.05 |
| SVRA Savara Inc. | Add +4.6% | 0.39% | −0.01 |
| XENE Xenon Pharmaceuticals Inc. | Add +9.4% | 0.99% | −0.05 |
| CBIO Crescent Biopharma Inc. | Add +8.7% | 0.69% | −0.08 |
| DRUG Bright Minds Biosciences Inc. | Add +10.7% | 0.89% | −0.11 |
| SGP Spyglass Pharma Inc. | Add +0.5% | 0.35% | −0.13 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $4.3B | BMRN, NBIX, ABVX, UTHR, ELVN |
| Q1 2026 | 90 | $3.6B | RVMD, BMRN, ABVX, NBIX, ARWR |
| Q4 2025 | 75 | $2.7B | ABVX, ACLX, TERN, BMRN, GMED |
| Q3 2025 | 80 | $2.2B | ASND, ACLX, NUVL, ABVX, ALC |
| Q2 2025 | 72 | $1.9B | ACLX, JAZZ, CYTK, NUVL, VERA |
| Q1 2025 | 63 | $1.4B | ACLX, CYTK, INSM, NUVL, VERA |
| Q4 2024 | 73 | $1.7B | JAZZ, CYTK, MRK, ASND, RARE |
| Q3 2024 | 67 | $1.3B | INSM, JAZZ, CYTK, NARI, ACLX |
| Q2 2024 | 60 | $1.3B | JAZZ, CYTK, ASND, RARE, GMED |
| Q1 2024 | 58 | $1.2B | CYTK, JAZZ, NBIX, ASND, GMED |